Increased expression of B7-H3 has been previously reported in multiple solid tumors, including pancreatic cancer. In a recent article, researchers from the University of Tuebingen discussed the development of a novel Fc-optimized monoclonal antibody (MAb) targeting B7-H3, named B7-H3-SDIE, as a new immunotherapeutic treatment option for pancreatic cancer.
Researchers at Guangzhou Salustier Biosciences Co. Ltd. and Jinan University (Guangdong) have identified selenium-containing heterocyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Cellectar Biosciences Inc. has released promising preclinical data for its proprietary novel α-emitting phospholipid radiotherapeutic conjugate, CLR-121225 (225Ac-CLR-121225), an actinium-labeled phospholipid ether, in refractory pancreatic cancer mouse xenograft models.
Quanta Therapeutics Inc. has announced progression of its pipeline of KRAS-directed drug candidates, with the receipt of IND approval from the FDA for QTX-3034.
Bispecific antibodies acting through CEACAM5/CD3 targeting have limited efficacy due to dose-limiting toxicities, insufficient T-cell activation and formation of anti-drug antibodies (ADAs). Researchers from Novimmune SA and Lampkap Bio Alpha AG have published data on a CEACM5/CD3 bispecific antibody, NILK-2301, which is formed by a heavy chain plus two different light chains (kappa and lambda body) as a potential immunotherapeutic with better efficacy and lower potential for ADA formation.
Starpharma Holdings Ltd.’s DEP docetaxel phase II trial met its primary endpoints, demonstrating antitumor activity in multiple advanced, metastatic cancers, including pancreatic, gastro-esophageal, non-small-cell lung cancer and cholangiocarcinoma.
The contribution of alternative RNA splicing in the progression of pancreatic ductal adenocarcinoma (PDAC) has not been deeply explored. In a recent study, the RNA-binding protein RNA binding fox-1 homolog 2 (RBFOX2) was investigated, since its role in modulating alternative splicing in PDAC is not well understood.
Starpharma Holdings Ltd.’s DEP docetaxel phase II trial met its primary endpoints, demonstrating antitumor activity in multiple advanced, metastatic cancers, including pancreatic, gastro-esophageal, non-small-cell lung cancer and cholangiocarcinoma.
